Abstract
We have studied the morphology and immunophenotype of circulating tumor cells isolated from peripheral blood of 22 patients with splenic marginal zone lymphoma and show that both of them are highly heterogeneous. Using a cell-binding microarray we have demonstrated that the circulating lymphoma cells are positive for CD19 (100 %), CD20 (100 %), CD22 (100 %), surface IgM (73 %), CD38 (23 %), CD5 (9 %), CD11c (36 %), CD103 (5 %), CD25 (32 %), CD23 (23 %) and these immunophenotypes are confirmed in all cases by flow cytometry. Higher surface density of lymphocyte binding onto anti-CD antibody microarray spots compared to blood smears permits to find circulating lymphoma cells even in leukopenic patients.
Highlights
Determination of morphology and immunophenotype of circulating lymphoma cells in patients with splenic marginal zone lymphoma using an anti-CD antibody microarray
We have studied the morphology and immunophenotype of circulating tumor cells isolated from peripheral blood of 22 patients with splenic marginal zone lymphoma and show that both of them are highly heterogeneous
Using a cell-binding microarray we have demonstrated that the circulating lymphoma cells are positive for CD19 (100 %), CD20 (100 %), CD22 (100 %), surface IgM (73 %), CD38 (23 %), CD5 (9 %), CD11c (36 %), CD103 (5 %), CD25 (32 %), CD23 (23 %) and these immunophenotypes are confirmed in all cases by flow cytometry
Summary
Determination of morphology and immunophenotype of circulating lymphoma cells in patients with splenic marginal zone lymphoma using an anti-CD antibody microarray. В периферической крови всех 22 пациентов с ЛКМЗС были обнаружены опухолевые клетки в количестве от 22 до 96 % (медиана 66 %) от всех лимфоцитов. Во всех 22 случаях ЛКМЗС опухолевые клетки экспрессировали CD19 (100 %), CD20 (100 %), CD22 (100 %) и были отрицательны по CD2, CD10, CD123, у части пациентов было показано связывание опухолевых клеток с анти-IgM (73 %), анти-CD38 (23 %).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
